Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
China
The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai, Shanghai Municipality